In the present study, by using pharmacological and genetic approaches we demonstrate that GPBAR1 activation protects against development of endothelial dysfunction in rodent models of portal hypertension, providing a molecular ground for the exploitation of GPBAR1 ligands in the treatment of portal hypertension in liver disorders. The gene discussed is GPBAR1; the disease is portal hypertension.